KMT2A and acute lymphoblastic leukemia: IKZF1 deletions were identified in 16% of patients with Ph-negative, KMT2A wild-type B-ALL, which conferred a 5-year cumulative incidence of relapse of 34% compared with 13% in IKZF1-non-deleted patients [34].